Thyroid hormones [predominantly 3,5,3′-triiodo-l-thyronine (T₃)] regulate cholesterol and lipoprotein metabolism, but cardiac effects restrict their use as hypolipidemic drugs. T₃ binds to thyroid hormone receptors (TRs) α and β. TRβ is the predominant isoform in liver, whereas T₃ effects on heart rate are mediated mostly by TRα. Drugs that target TRβ or exhibit tissue-selective uptake may improve plasma lipid levels while sparing the heart. Here, we asked how the TRβ- and liver uptake-selective agonist GC-1 influences cholesterol and triglyceride metabolism in euthyroid mice. GC-1 treatment reduced serum cholesterol levels by 25% and serum triglycerides by 75% in chow-fed mice and also attenuated diet-induced hypercholesterolemia. GC-1 reduced plasma high-density lipoprotein cholesterol levels; increased expression of the hepatic high-density lipoprotein receptor, SR-BI; stimulated activity of cholesterol 7α-hydroxylase; and increased fecal excretion of bile acids. Collectively, these results suggest that GC-1 stimulates important steps in reverse cholesterol transport. Use of TRβ and uptake selective agonists such as GC-1 should be further explored as a strategy to improve lipid metabolism in dyslipoproteinemia.